Elotuzumab, Selinexor, and Dexamethasone for Relapsed Refractory Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The food and drug administration (FDA) has approved the use of Selinexor, an oral, first-in
class, exportin 1 (XPO1) inhibitor, in combination with low-dose dexamethasone in patients
with triple-refractory (disease refractory to proteasome inhibitors (PI), immunomodulatory
imid agents (IMiD), and anti-Cluster of Differentiation 38 (CD38) monoclonal antibodies
(mAb)), or relapsed refractory multiple myeloma (RRMM). SLAMF7 (human Signaling Lymphocyte
Activation Molecule Family 7) is a receptor that is present on immune cells, NK (Natural
Killer) cells, and plasma cells. Elotuzumab, a mAb directed against the extracellular domain
of SLAMF7, is used in combination with an IMiD and dexamethasone to treat RRMM. In this
clinical trial, the investigators are proposing the addition of Elotuzumab to Selinexor and
low-dose dexamethasone (ESd) in RRMM, previously treated with one or a combination of PI's,
IMiD's, and anti-CD38 mAb.